These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 1462166)

  • 21. [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
    Vasyuk YA; Shkolnik EL; Nesterov VV; Shkolnik LD; Varlan GV
    Kardiologiia; 2016 Dec; 56(12):72-79. PubMed ID: 28290807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer.
    Judson IR
    Semin Oncol; 1992 Dec; 19(6):687-94. PubMed ID: 1462167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites.
    Boven E; de Jong J; Kuiper CM; Bast A; van der Vijgh WJ
    Eur J Cancer; 1996 Jul; 32A(8):1382-7. PubMed ID: 8869103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
    Simůnek T; Stérba M; Popelová O; Adamcová M; Hrdina R; Gersl V
    Pharmacol Rep; 2009; 61(1):154-71. PubMed ID: 19307704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New anthracyclines in the treatment of solid tumors in the advanced stage].
    Pannuti F; Martoni A; Lelli G; Camaggi CM; Strocchi E; Fruet F
    G Ital Chemioter; 1985; 32(1):49-56. PubMed ID: 3868636
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
    Robert J
    Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
    Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F
    Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.
    Mordente A; Minotti G; Martorana GE; Silvestrini A; Giardina B; Meucci E
    Biochem Pharmacol; 2003 Sep; 66(6):989-98. PubMed ID: 12963485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
    Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
    J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.
    Bárdi E; Bobok I; V Oláh A; Kappelmayer J; Kiss C
    Pathol Oncol Res; 2007; 13(3):249-53. PubMed ID: 17922055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current status of clinical results of new antitumor drugs].
    Ogawa M
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):179-88. PubMed ID: 3918502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
    Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
    Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental evaluation of anthracycline analogs.
    Casazza AM
    Cancer Treat Rep; 1979 May; 63(5):835-44. PubMed ID: 455325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
    Swift L; McHowat J; Sarvazyan N
    Cancer Res; 2003 Sep; 63(18):5992-8. PubMed ID: 14522926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.